A single arm open-label multicenter phase II study of 177Lu-DOTATATE radionuclide in adults with progressive or high-risk meningioma

Brief description of study

The purpose of this research study is to test whether Lutathera® (177Lu-DOTATATE) is effective (how well something works) at stopping the growth of meningiomas. This study will also test whether Lutathera® causes any side effects in patients with meningioma. “Investigational” means that the drug is not approved by the US Food and Drug Administration (FDA) for clinical (patient) use for a specific disease, but can be studied in a clinical trial like this one. Lutathera® (177Lu-DOTATATE) has been approved by the FDA for the treatment of a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin. These include neuroendocrine tumors in the foregut, midgut, and hindgut in adults.

Clinical Study Identifier: s18-00719
ClinicalTrials.gov Identifier: NCT03971461

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.